FusionVax Snags Exclusive Rights to HPV Drug in Asia – Genetic Engineering News

FusionVax Snags Exclusive Rights to HPV Drug in Asia
Genetic Engineering News
Advaxis has exclusively licensed its lead clinical-stage product candidate, ADXS-HPV, to FusionVax. Under the terms of the agreement, Advaxis will license the rights to ADXS-HPV for the Asia territory, exclusive of India, for all indications. In

View full post on hpv – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *